Literature DB >> 20308465

Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.

Irene Bargellini1, Claudio Vignali, Roberto Cioni, Pasquale Petruzzi, Antonio Cicorelli, Daniela Campani, Paolo De Simone, Franco Filipponi, Carlo Bartolozzi.   

Abstract

PURPOSE: To retrospectively evaluate the clinical outcome of patients with hepatocellular carcinoma (HCC) who exceeded the Milan criteria, who underwent transarterial chemoembolization (TACE) before orthotopic liver transplantation (OLT), to determine the value of computed tomography (CT)-based tumor response to TACE as a preoperative selection criterion for OLT.
MATERIALS AND METHODS: The study included 33 patients with HCC who exceeded the Milan criteria and underwent OLT after TACE. Informed written consent was obtained before TACE and OLT. Institutional review board approval was not required. Tumor response to TACE was evaluated at 1 month with CT according to amended Response Evaluation Criteria in Solid Tumours (RECIST) guidelines. In the explanted liver, degree of tumor necrosis (> or = 90%, 50%-89%, or < 50%), residual tumor stage and grade, and presence of microvascular invasion were assessed. Follow-up after OLT ranged from 1 to 143 months.
RESULTS: After TACE, CT showed complete tumor response (CR) in 18 (55%) patients. On the explanted liver, tumor necrosis was rated 90% or greater in 20 (61%) patients, with a good correlation with CT. Microvascular invasion was observed in nine (27%) of 33 patients; none of them were reported to have a CR at CT. The 5-year cumulative survival rate after OLT was 72.5%; it was significantly (P = .003) higher in patients with a CR (94.4%) compared with patients with a partial response (PR) (45.4%) and stable disease (50%). The 5-year cumulative recurrence-free rate after OLT was 74.4%; it was not affected by the tumor nodule size and number, whereas it was significantly (P = .008) higher in patients with a CR (94.4%) compared with patients with a PR (46.7%) and stable disease (50%).
CONCLUSION: In patients with HCC who exceeded the Milan criteria, a CR after TACE, on the basis of amended RECIST guidelines, is associated with excellent posttransplantation outcomes. Therefore, 1-month response to TACE assessed at CT may represent a valid selection criterion for OLT. RSNA, 2010

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308465     DOI: 10.1148/radiol.09090927

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  23 in total

1.  Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.

Authors:  Hyung-Don Kim; Gi-Won Song; Ju Hyun Shim; Seungbong Han; Jihyun An; Deok-Bog Moon; Kang Mo Kim; Young-Suk Lim; Gi-Young Ko; Shin Hwang; Han Chu Lee; Eunsil Yu; Kyu-Bo Sung; Sung-Gyu Lee
Journal:  Hepatol Int       Date:  2017-01-31       Impact factor: 6.047

2.  [Contrast-enhanced sonography. Therapy control of radiofrequency ablation and transarterial chemoembolization of hepatocellular carcinoma].

Authors:  E M Jung; W Uller; C Stroszczynski; D-A Clevert
Journal:  Radiologe       Date:  2011-06       Impact factor: 0.635

3.  Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.

Authors:  Olivio F Donati; Richard Kinh Gian Do; Andreas M Hötker; Seth S Katz; Junting Zheng; Chaya S Moskowitz; Christopher Beattie; Karen T Brown
Journal:  Eur Radiol       Date:  2015-04-08       Impact factor: 5.315

4.  What's New in Transarterial Therapies for Hepatocellular Carcinoma?

Authors:  Benjamin J May; Ravi Murthy; David C Madoff
Journal:  Gastrointest Cancer Res       Date:  2012-05

Review 5.  Assessment of response to therapy in hepatocellular carcinoma.

Authors:  Tushar Patel; Denise Harnois
Journal:  Ann Med       Date:  2014-04-10       Impact factor: 4.709

6.  Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation.

Authors:  Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Young-Dong Yu; Pyoung-Jae Park; Young-Il Choi; Kyoung-Won Kim; Young-Suk Lim; Han Chu Lee; Eun-Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2011-03-29       Impact factor: 3.452

Review 7.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

10.  Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.

Authors:  Daniele Nicolini; Gianluca Svegliati-Baroni; Roberto Candelari; Cinzia Mincarelli; Alessandra Mandolesi; Italo Bearzi; Federico Mocchegiani; Andrea Vecchi; Roberto Montalti; Antonio Benedetti; Andrea Risaliti; Marco Vivarelli
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.